A Case of Superficial Giant Basal Cell Carcinoma with Satellite Lesions on Scalp by Heo, Young Soo et al.
Vol. 23, Suppl. 1, 2011 S111
Received December 28, 2009, Revised August 18, 2010, Accepted for 
publication October 22, 2010
Corresponding author: Soo Hong Seo, M.D., Department of Derma-
tology, Korea University Anam Hospital, 126-1 Anam-dong, Seobuck- 
gu, Seoul 136-071, Korea. Tel: 82-2-920-5473, Fax: 82-2-838-2359,
E-mail: drsshong@medimail.co.kr
This is an Open Access article distributed under the terms of the 
Creative Commons Attribution Non-Commercial License (http:// 
creativecommons.org/licenses/by-nc/3.0) which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, 
provided the original work is properly cited.
Ann Dermatol Vol. 23, Suppl. 1, 2011 http://dx.doi.org/10.5021/ad.2011.23.S1.S111
CASE REPORT
A Case of Superficial Giant Basal Cell Carcinoma with 
Satellite Lesions on Scalp
Young Soo Heo, M.D., Jung Hee Yoon, M.D., Jae Eun Choi, M.D., Hyo Hyun Ahn, M.D., 
Yonug Chul Kye, M.D., Soo Hong Seo, M.D.
Department of Dermatology, College of Medicine, Korea University, Seoul, Korea
Giant basal cell carcinoma (BCC), defined as a lesion greater 
than 5 cm at its largest diameter, is a rare variant of BCC. In 
contrast to small BCC, giant BCC develops on skin that is not 
exposed to sunlight, including the back, shoulder, groin and 
thigh. Most of the histopathologic subtypes of giant BCC are 
micronodular, morpheaform and nodular, but the superficial 
subtype is rare. Giant superficial BCC arising on the scalp is 
extremely rare. We report the case of giant superficial BCC 
with four satellite lesions on the scalp in a 53-year-old male 
without predisposing factors. (Ann Dermatol 23(S1) S111∼
S115, 2011)
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INTRODUCTION
Basal cell carcinoma (BCC) is the most common human 
cancer. Most are small and usually occur on sun-exposed 
areas. The rare variant designated giant BCC has an 
unusually large size (＞5 cm in diameter) and often 
develops multiple lesions, which frequently occur on skin 
that is not typically exposed to sunlight, including the 
back, shoulder, groin and thigh
1-3. Patients with giant BCC 
are more likely to have a tumor that displays an aggressive 
histologic subtype (morpheaform, micronodular, or 
metatypical)
2. Giant superficial BCCs limited to the scalp 
are exceedingly rare. We report a case of giant BCC with 
four satellite lesions on the scalp that was treated with 5% 
imiqumoid cream and cryosurgery.
CASE REPORT
A 54-year-old man presented with an asymptomatic dark- 
colored patch on the frontal scalp. The lesion had been 
growing very slowly for 15 years, without concern or 
need for medical attention by the patient. The patient was 
in good health with no pertinent medical history or 
concurrent symptoms. There was also nothing contributory 
from his family history.
Physical examination revealed a 6×8 cm, well-defined, 
round black-colored patch on the frontal scalp. On closer 
examination, four other dark-colored macules were 
observed around the main lesion (Fig. 1A). Regional lymph 
nodes were not palpable and the remainder of physical 
examination was not contributory. Laboratory test results 
including complete blood cell count, urine analysis, liver 
function test, chest X-ray and electrocardiogram were 
within normal limits or negative.
Biopsy specimens were obtained from the center of main 
lesion and the four satellite lesions. A biopsy specimen 
from the main lesion showed budding and irregular 
proliferation of tumor tissue attached to the undersurface 
of the epidermis. The peripheral cell layer of the tumor 
formations usually displayed palisading. In addition, a mild 
amount of a nonspecific chronic inflammatory infiltrate 
was present in the upper dermis, which is a typical feature 
for superficial BCC (Fig. 1B, C). A biopsy specimen taken 
from the satellite lesions showed similar histological 
findings (Fig. 2).Y S  H e o ,  e t  a l
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Fig. 1. (A) 6×8 cm sized irregular shaped round pigmented patch with 4 satellite macules on saclp. (B) Tumor shows buds and
irregular proliferations of tumor tissue attached to the undersurface of the epidermis (H&E, ×40). (C) The tumor cells have a large, 
unifrom, oval, nonanaplatic-appearing nucleus with little cytoplasm (H&E, ×100).
The giant BCC was treated a combination of with 5% 
imiquimod and cryosurgery combination, given the 
patient’s reluctance for an operation and since the lesion 
was too large to recover by a skin graft. Cryosurgery 
consisted of 2∼3 freeze-thaw cycles (15 seconds of 
freezing with an intervening 60 second thaw period). Four 
days later, the patient topically applied 5% imiquimod 
once. This procedure was done four time. Topical 
treatment with imiquimod cream was then continued for 4 
months. The satellite lesions were addressed by simple 
excision with a 3 mm margin; free margin resection 
resulted.
Two months after the last treatment, a clinical examination 
revealed only atrophic and hypo-pigmented areas, without 
any signs of residual tumor (Fig. 3A). Seven months later, 
follow-up biopsies were performed at three points (center, 
6 o’clock and 12 o’clock) at the original site of the giant 
BCC; the biopsy samples demonstrated only cicatricial 
fibrosis. At the time of manuscript submission, the patient 
has been under complete remission for 1 year (Fig. 3B-D).
DISCUSSION
The American Joint Committee on Cancer Classification of 
tumors is based on the largest diameter: (T1, ≤2 cm; T2, 
＞2 cm but ＜5 cm; T3, ≥5 cm). Giant BCC is a T3 
tumor
2.
Giant BCC presents some common epidemiological factors 
that include race, multiplicity of tumors, development on 
sun-covered areas, neglect and tumor chronicity
3. Fear 
may be the underlying factor leading to neglect and 
chronicity of the tumor
2. Immunodeficiency and genetic 
predisposition to BCC in other family members are not 
consistent factors
3. In contrast to patients who develop a 
single small BCC, giant BCC frequently develops on skin 
that is not typically exposed to sunlight, including the 
back, shoulder, leg and thigh
3. The scalp is not a 
commonly-reported site of giant BCC. Yet, it is conceivable 
that the presence of scalp hair allows a patient who is 
fearful of the findings of a medical examination to conceal 
the tumor
4, allowing the tumor to become chronic and A Case of Superficial Giant Basal Cell Carcinoma with Satellite Lesions on Scalp
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Fig. 2. In satellite lesions from right to left on the scalp. Histopathologic finding showed budding of basaloid cells from the basal
layer into the upper dermis, with peripheral palisading and clefting (H&E,×40).
large in size.
Histopathological subtypes of BCC can be grouped as 
nonaggressive (nodular and superficial subtypes) and 
aggressive (morpheaform, micronodular and metatypical 
subtypes)
1,2. In a review of 50 cases of giant BCC, 35 cases 
(72%) presented an aggressive histopathological subtypes, 
13 cases (26%) presented the nodular subtype with only a 
single case (2%) being the superficial subtype
2.
For the treatment of giant BCC, a variety of modalities 
have been used with inconsistent results. Treatments 
include surgical excision and grafting, Mohs micrographic 
surgery or radiation therapy
5, with gold standard treatment 
for large BCC being Mohs surgery. But, surgery carries an 
increased risk of morbidity since extremely large skin 
grafts are needed to an area predisposed to hypertrophic 
scars and keloids
6. If patients refuse surgery and skin 
grafting, alternative treatments must be chosen.
Cryosurgery is widely-accepted for the treatment of 
well-defined small BCC. Reports have been published 
demonstrating good results for tumors up to 10 cm
7. 
Recently, giant lesions of superficial BCC were successfully 
treated by cryosurgery, yielding quite good cosmetic 
results
8. Tissue destruction by cryosurgery starts by the 
immediate necrosis of treated cells (“physical” phase) and is 
further strengthened by destruction of the microcirculation 
of the tumor (“vascular” phase), and as a result of tumor 
inflammation, probably driven by cryosurgery-triggered 
liberation of tumor antigens in the organism (“immuno-
logical” phase)
9,10.
Similarly, imiquimod has been shown to be effective in 
the treatment of superficial and nodular BCC with efficacy 
approaching surgical or ablative modalities. Besides being 
a potent immune response modifier and stimulator of both 
innate and adaptive immunity, imiquimod induces apop-
tosis either by inducing the pro-apoptotic Fas receptor 
(FasR) or, upon uptake into the cell, by direct intracellular 
activation of the apoptotic cascade. The result is inhibited 
angiogenesis by different mechanisms
11,12. Combination 
therapy of cryosurgery and 5% imiquimod may reinforce 
apoptosis of the tumor cells, strengthen anti-angiogenesis Y S  H e o ,  e t  a l
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Fig. 3. (A) Two months after the last treatment, lesions revealed only atrophic and hypo-pigmented scar change. (B~D) 7 months
later of treatment, follow up biopsies showed only cicatricial fibrosis (B: Center, C: 6 o'clock, D: 12 o'clock).
in the treated tumor and build-up a potent tumor-destructive 
immune response by a cascade of events starting with imi-
quimod-promoted attraction of immature dendritic anti-
gen-presenting cells into the tumor. Dentritic cells further 
mature within the tumor antigen-rich environment of the 
subsequently cryo- destructed tumor and, upon imiqui-
mod driven migration into the peripheral lymph nodes, 
can stimulate specific antineoplastic cell-mediated 
immunity. Finally, continuing imiquimod application after 
cryosurgery increase recruitment of activated effector cells 
into the tumor tissue leads to its destruction
12.
In summary, we report a case of giant superficial BCC 
with four satellite lesions on the scalp. Our patient is of 
interest because of the unusual size, histology and the 
presence of the satellite lesions. Although further studies 
are needed to determine the exact causes of this 
phenomenon, this is the first case of giant superficial BCC 
with multiple satellite lesions that treated 5% imiqumoid 
cream and cryosurgery combination therapy.
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